S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
NASDAQ:IMMP

Immutep (IMMP) Stock Price, News & Analysis

$2.41
+0.02 (+0.84%)
(As of 10:17 AM ET)
Today's Range
$2.37
$2.47
50-Day Range
$2.11
$2.89
52-Week Range
$1.50
$3.90
Volume
17,227 shs
Average Volume
130,041 shs
Market Capitalization
$211.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Immutep MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
255.6% Upside
$8.50 Price Target
Short Interest
Bearish
1.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Immutep in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.31) to ($0.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.04 out of 5 stars

Medical Sector

730th out of 939 stocks

Pharmaceutical Preparations Industry

339th out of 436 stocks

IMMP stock logo

About Immutep Stock (NASDAQ:IMMP)

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

IMMP Stock Price History

IMMP Stock News Headlines

Immutep Ltd Sponsored ADR
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Immutep: Upcoming Signals For 2024 (Maintain Buy)
Immutep Limited (IMMP)
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Immutep to Participate in November Investor Events
Immutep receives ~A$1.13 million R&D Tax Incentive
Immutep to Participate in September Investor Conferences
Robert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)
IMMP - Immutep Limited
See More Headlines
Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMMP
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+255.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.50 million
Book Value
$1.04 per share

Miscellaneous

Free Float
85,231,000
Market Cap
$210.15 million
Optionable
Optionable
Beta
2.15
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Marc Voigt (Age 51)
    CEO, MD, CFO, Chief Business Officer & Executive Director
    Comp: $371.23k
  • Ms. Deanne Miller LLB (Age 47)
    COO, General Counsel & Joint Company Secretary
    Comp: $242.76k
  • Dr. Frederic Triebel M.D. (Age 69)
    Ph.D., Chief Scientific Officer & Executive Director
    Comp: $296.34k
  • Mr. Christian Mueller BBA
    MSc., Senior Vice President of Regulatory & Strategy
  • Mr. Florian D. Vogl M.D.
    M.Sc., Ph.D., Chief Medical Officer
  • Ms. Indira Naidu
    Joint Company Secretary

IMMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Immutep stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares.
View IMMP analyst ratings
or view top-rated stocks.

What is Immutep's stock price target for 2024?

1 brokers have issued 12-month target prices for Immutep's stock. Their IMMP share price targets range from $7.00 to $10.00. On average, they predict the company's share price to reach $8.50 in the next year. This suggests a possible upside of 255.6% from the stock's current price.
View analysts price targets for IMMP
or view top-rated stocks among Wall Street analysts.

How have IMMP shares performed in 2024?

Immutep's stock was trading at $2.40 on January 1st, 2024. Since then, IMMP stock has decreased by 0.4% and is now trading at $2.39.
View the best growth stocks for 2024 here
.

Are investors shorting Immutep?

Immutep saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,140,000 shares, an increase of 5.6% from the February 29th total of 1,080,000 shares. Based on an average daily trading volume, of 130,400 shares, the days-to-cover ratio is currently 8.7 days.
View Immutep's Short Interest
.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

Who are Immutep's major shareholders?

Immutep's stock is owned by many different institutional and retail investors. Top institutional investors include Meridian Wealth Management LLC (0.37%), BNP Paribas Financial Markets (0.03%), GTS Securities LLC (0.03%), Citadel Advisors LLC (0.00%), Virtu Financial LLC (0.01%) and Simplex Trading LLC (0.00%).

How do I buy shares of Immutep?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMMP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners